This multi-centre study will evaluate the clinical efficacy of 3 atypical antipsychotics treatment in Chinese Patients with Schizophrenia by comparing model-decision with real-world psychiatrist-decision. The three atypical antipsychotics are olanzapine (5-20 milligram per day), risperidone (2-6 milligram per day) and aripiprazole (5-30 milligram per day). The main purpose of this study is to explore the potential difference between modal-aided-decision with clinician-decision in order to validate and optimize the selection model that has been established in advance. The efficacy evaluations include symptoms, social function, recurrence rate and hospitalization. Visits occurs at 0, 4, 8, 13, 26, 52 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
2,000
a model that has been established in advance.
real-world psychiatrist decision
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
RECRUITINGChange of PSP from Baseline
PSP assessment at 52 weeks
Time frame: 52 weeks
Change of PANSS from Baseline
PANSS assessment at 52 weeks
Time frame: 52 weeks
Change of CDSS from Baseline
CDSS assessment at 52 weeks
Time frame: 52 weeks
Change of CGI from Baseline
CGI assessment at 52 weeks
Time frame: 52 weeks
Change of liver function from Baseline
Liver function assessment at 52 weeks
Time frame: 52 weeks
Change of PRL from Baseline
PRL assessment at 52 weeks
Time frame: 52 weeks
Number of Participants with EPS
EPS assessment at 52 weeks
Time frame: 52 weeks
Number of Participants with abnormal ECG
ECG assessment at 52 weeks
Time frame: 52 weeks
Number of Participants with abnormal sexual function
sexual function assessment at 52 weeks
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.